Stockscreener 앱 받기
0.15%
시간 외 거래:
전일 마감가:
$27.56
열려 있는:
$27.585
하루 거래량:
24.44M
Relative Volume:
0.57
시가총액:
$156.54B
수익:
$62.58B
순이익/손실:
$7.79B
주가수익비율:
20.31
EPS:
1.3551
순현금흐름:
$9.08B
1주 성능:
+0.66%
1개월 성능:
+2.04%
6개월 성능:
+11.46%
1년 성능:
+24.30%
1일 변동 폭
$27.51
$27.84
1주일 범위
$26.97
$27.84
52주 변동 폭
$21.87
$28.75
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.52 | 156.77B | 62.58B | 7.79B | 9.08B | 1.3551 |
LLY
Lilly Eli Co
|
919.90 | 828.17B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
230.69 | 564.05B | 96.36B | 21.04B | 19.70B | 8.6488 |
ABBV
Abbvie Inc
|
203.71 | 368.57B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
200.69 | 317.61B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
117.10 | 294.09B | 64.93B | 18.26B | 12.36B | 7.2751 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 업그레이드 | Argus | Hold → Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Underperform |
| 2026-02-20 | 개시 | Barclays | Underweight |
| 2026-02-12 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
Pfizer Oncology Outlook Shifts As PADCEV Keytruda Win Nears FDA Decision - simplywall.st
Pfizer’s PADCEV Keytruda Priority Review Tests Bladder Cancer And Valuation Story - Yahoo Finance
Pfizer's Andrew Baum to Transition Role Amid Strategic Simplification - GuruFocus
CICC Initiates Coverage of Pfizer Inc. (PFE) With an Outperform Rating - Yahoo Finance
Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says - Reuters
Pfizer Inc. stock (US7170811035): Why does its post-COVID pivot matter more now for investors? - AD HOC NEWS
Mizuho reiterates BridgeBio stock rating ahead of Pfizer trial By Investing.com - Investing.com Canada
FDA Grants Priority Review for Pfizer and Astellas' Padcev with Keytruda for Bladder Cancer - Intellectia AI
Pfizer, Astellas win FDA priority review for Padcev (PFE:NYSE) - Seeking Alpha
Pfizer (PFE) and Amgen (AMGN) Expand Presence in Hong Kong - GuruFocus
Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP (PFE:NYSE) - Seeking Alpha
Seagen Inc (Acquired) stock (US8166361055): Why does its oncology pipeline still matter post-acquisi - AD HOC NEWS
Pfizer Impfstoff (Comirnaty): Post-Pandemic Revenue Drop Sparks Strategy Shift - AD HOC NEWS
Pfizer Impfstoff (Comirnaty): Post-Pandemic Pivot Challenges Traditional Vaccine Revenue - AD HOC NEWS
Where will Pfizer stock be in 3 years? - MSN
This Drug Stock Has Crushed the S&P 500 Over the Last Decade - The Motley Fool
Pfizer Inc. stock (US7170811035): Is its post-COVID pivot strong enough to unlock new upside? - AD HOC NEWS
Lobbying Update: $4,420,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Where Will Pfizer Stock Be in 3 Years? - Yahoo Finance
Pfizer’s COVID Reset Shifts Focus To Obesity Pipeline And Valuation Risks - simplywall.st
Pfizer (PFE) Valuation Check As COVID Decline And Obesity Pipeline Shift Reshape Its Outlook - Yahoo Finance
Mirae Asset Global Investments Co. Ltd. Acquires 177,689 Shares of Pfizer Inc. $PFE - MarketBeat
PFE Stock Quote Price and Forecast - CNN
Pfizer (NYSE:PFE) Trading Up 1.3%What's Next? - MarketBeat
Wilson’s Disease Market to Reach New Heights by 2034 with Advancing Gene Therapies and Strong Pipeline from Vivet Therapeutics, Pfizer, and Ultragenyx Pharmaceutical | DelveInsight - Barchart.com
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Pfizer Patent Suits Seek to Block Competitors’ Dermatitis Drugs - Bloomberg Law News
Pfizer Impfstoff (Comirnaty): Post-Pandemic revenue drop raises big questions for Pfizer's future - AD HOC NEWS
Records Show Pfizer Used Sick Monkeys in Drug Testing, PETA Urges Review - PETA
Rebalancing Agents Hympavzi (Pfizer), Qfitlia (Sanofi), Alhemo (Novo Nordisk) Gain Ground in Hemophilia as Physicians Navigate Access Barriers and Expanding Treatment Complexity - Yahoo Finance
Pfizer (NYSE: PFE) CEO receives phantom stock unit award under deferred plan - Stock Titan
AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit - Yahoo Finance
Pfizer Stock: Painful Recovery Underway (NYSE:PFE) - Seeking Alpha
Wright Investors Service Inc. Purchases 56,743 Shares of Pfizer Inc. $PFE - MarketBeat
Meropenem Market Is Booming So Rapidly | Merck & Co. • Pfizer Inc. • AstraZeneca - openPR.com
Argo Wealth Advisory LLC Takes Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Acquired by AE Wealth Management LLC - MarketBeat
Pfizer (PFE) CEO Albert Bourla receives 911 phantom stock units as deferred pay - Stock Titan
Pfizer Inc (PFE) Stock Price, Trades & News - GuruFocus
Pfizer-Backed EV-209 Trial Targets Bladder Preservation in High-Need Cancer Segment - TipRanks
Pfizer stock price forecast: sideways trading expected as PFE consolidates above key supports - Traders Union
Here Are Thursday’s Top Wall Street Analyst Research Calls: Autoliv, CoreWeave, Corning, Dicks Sporting Goods, Federated Hermes, Gitlab, PayPal, Pfizer, Okta, and More - 24/7 Wall St.
Lbp Am Sa Has $25.32 Million Stake in Pfizer Inc. $PFE - MarketBeat
KBC Group NV Purchases 706,426 Shares of Pfizer Inc. $PFE - MarketBeat
CICC Initiates Pfizer at Outperform With $33 Price Target - marketscreener.com
Assessing Pfizer (PFE) Valuation As Investor Interest Returns And Turnaround Expectations Build - simplywall.st
DND Pharmatech Wins KRW1.83 Billion Anti-Obesity Drug Formulation Contract from Pfizer; Shares Rise 3% - marketscreener.com
New weight loss drug by Pfizer shows promising results in trial - AOL.com
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings - Yahoo Finance
How Biomarker Testing Helped a Lung Cancer Patient Get the Treatment She Needed - Pfizer
Pfizer Inc. $PFE Shares Sold by Freestone Capital Holdings LLC - MarketBeat
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
자본화:
|
볼륨(24시간):